Cepheid

The FDA cleared Cepheid's C. difficile test to run on its GeneXpert System. The firm expects to begin shipments next week.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Cepheid and the University of Medicine and Dentistry of New Jersey will work on developing a 10-color detection technology for the firm's GeneXpert System.

The GWDN Index of 36 molecular biology tools and molecular diagnostics makers gained ground for the second month in a row, with Affymetrix rising significantly during that time period. Sequenom's tumble occurred on the final day of the month.

The test simultaneously identifies Mycobacterium tuberculosis and resistance to first-line drug therapy rifampicin.

Cepheid's new assay is the 10th Xpert molecular test to receive the CE-IVD Mark.

People in the News

Mari Baker is leaving Navigenics, Andrew von Eschenbach has joined a consulting firm, Jay Flatley takes a seat on Helixis' board, and more.

The molecular diagnostics firm's decline in sales to clinical partners and biothreat customers was the primary cause of its expected decrease in Q4 revenues. It also announced a series of measures aimed at reining in costs in 2009.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.